Age (y) | | | 0.685 |
< 50 | 59 | 52 | |
≥ 50 | 101 | 98 | |
Tumor size (mm) | | | 0.500 |
< 20 | 76 | 77 | |
≥ 20 | 84 | 73 | |
TNM stage | | | 0.849 |
I | 19 | 15 | |
II | 66 | 65 | |
III | 75 | 70 | |
Histological differentiation | | | 0.905 |
I/II | 96 | 89 | |
III | 64 | 61 | |
Positive lymph node ratio | | | 0.628 |
< 0.21 | 59 | 50 | |
0.21 ≤ x < 0.65 | 80 | 75 | |
≥0.65 | 21 | 25 | |
Receptor status | | | |
ER | | | 0.602 |
Positive | 51 | 52 | |
Negative | 109 | 98 | |
PR | | | 0.877 |
Positive | 75 | 69 | |
Negative | 85 | 81 | |
Her2 | | | 0.604 |
Positive | 60 | 52 | |
Negative | 100 | 98 | |
PD-L1 expression | | | 0.264 |
Positive | 42 | 44 | |
Negative | 118 | 106 | |
Chemotherapy | | | 0.549 |
Yes | 150 | 138 | |
No | 10 | 12 | |
Radiotherapy | | | 0.267 |
Yes | 149 | 144 | |
No | 11 | 6 | |
Endocrinetherapy | | | 0.136 |
Yes | 109 | 90 | |
No | 51 | 60 | |
TNBC | | | 0.952 |
Yes | 26 | 24 | |
No | 134 | 126 | |